TP53 and acute myeloid leukemia: Nonetheless, the median overall survival of TP53 mutant AML patients treated with decitabine remains <1 year [7]; the addition of venetoclax, a promising inhibitor of the antiapoptotic BCL-2 protein, did not improve decitabine treatment [8].